16
Participants
Start Date
July 31, 2012
Primary Completion Date
May 31, 2015
Study Completion Date
April 30, 2016
Pazopanib and paclitaxel
Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
Imperial College Healthcare NHS Trust, London
Southend University Hospital NHS Foundation Trust, Southend
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Imperial College London
OTHER